The US Food and Drug Administration (FDA) last week lifted the clinical hold on Intellia Therapeutics’ investigational new drug (IND) for its nexiguran ziclumeran (nex-z) for amyloidosis. The US ...
Danish CNS company Lundbeck announced six-month data from the 12-month, real-world INFUSE study, evaluating the effectiveness ...
Japanese drugmaker Kyowa Kirin late Friday announced the termination of the current rocatinlimab development and commercialization collaboration with US biotech major Amgen.